Evidence mapPaperPMID 39780311Full record

ArticleDiabetes, obesity & metabolism2025

Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes.

Aleksander L Hansen, Mette K Andersen, Leonie M Engelhard, Charlotte Brøns, Torben Hansen, Jens S Nielsen, Peter Vestergaard, Kurt Højlund, Niels Jessen, Michael H Olsen and 2 more

Abstract read
In one paragraph

Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Integrative Clinical and Functional Characterization of theDiagnostics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. International journal of medical sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aleksander L HansenSteno Diabetes Center Copenhagen, Herlev, Denmark.ORCID 0000-0002-9514-8942
Mette K AndersenNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-8227-1469
Leonie M EngelhardSteno Diabetes Center Copenhagen, Herlev, Denmark.ORCID 0009-0008-9496-1297
Charlotte BrønsSteno Diabetes Center Copenhagen, Herlev, Denmark.ORCID 0000-0002-6653-9020
Torben HansenNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-8748-3831
Jens S NielsenSteno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.ORCID 0000-0003-3179-1186
Peter VestergaardSteno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark.ORCID 0000-0002-9046-2967
Kurt HøjlundSteno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.ORCID 0000-0002-0891-4224
Niels JessenSteno Diabetes Center, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0001-5613-7274
Michael H OlsenDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-2230-5780
Reimar W ThomsenDepartment of Clinical Epidemiology, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0001-9135-3474
Allan VaagSteno Diabetes Center Copenhagen, Herlev, Denmark.ORCID 0000-0002-3690-2191

Funding

Danish Agency for Science and Higher Education 09-067009Danish Agency for Science and Higher Education 09-075724DiabetesforeningenNovo Nordisk Fonden NNF17SA0030364Novo Nordisk Fonden NNF17SA0030962-2Novo Nordisk Fonden NNF20O0063292Novo Nordisk Fonden NNF23SA0084103Region SyddanmarkSundhedsstyrelsenSwedish Research Council 2009-1039Swedish Research Council 2018-02837
6 · The paper itself

Abstract

aimsTCF7L2 rs7903146 is the most impactful single genetic risk variant for type 2 diabetes. However, its role on disease progression, complications and mortality among people with type 2 diabetes at diagnosis remains unclear. MATERIALS AND

methodsWe assessed the per allele impact of the rs7903146 T-allele on clinical characteristics and complication risk in 9231 individuals with type 2 diabetes at diagnosis and over a 10-year follow-up period. Log-binomial and robust Poisson regression analyses were used to estimate prevalence ratios for clinical characteristics and macro- and microvascular complications at diabetes onset, while Cox regression was applied to estimate the risk of complications post-diagnosis. Analyses were adjusted for sex, calendar year at birth, age at enrollment and diabetes duration.

resultsThe per T-allele impact was associated with 0.6 kg/m

conclusionsThe TCF7L2 variant is associated with less obesity, lower insulin secretion and higher insulin action at diabetes onset, and decreased risk of cardiovascular events following type 2 diabetes onset.

Indexed as

Diabetes ComplicationsDiabetes Mellitus, Type 2Diabetic AngiopathiesTranscription Factor 7-Like 2 ProteinAdultAgedAllelesFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPolymorphism, Single NucleotideRisk FactorsTCF7L2 protein, humanTranscription Factor 7-Like 2 Proteincardiovascular diseasecohort studydiabetes complicationsgenetic predispositionobservational studytype 2 diabetes

Identifiers

PMID39780311
PMCPMC11885091

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.